rg4733
Adult Brain Stem Glioma
National Cancer Institute (NCI)Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 26/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adult Brain Stem Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 1 | CCC |
Alisertib Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 | CC |
FDOPA Erik Mittra | Early Phase 1 | CC |
EF-5 National Cancer Institute (NCI) | Phase 1 | C |
Gadobutrol University of Southern California | N/A | D |
GADOBENATE DIMEGLUMINE University of Southern California | N/A | D |
Same molecule, other indications
rg4733 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →